Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma. (17th October 2018)

• Record Type: Journal Article
• Authors: Li, Jian‐Ri; Chiu, Kun‐Yuan; Ou, Yen‐Chuan; Wang, Shian‐Shiang; Chen, Chuan‐Su; Yang, Cheng‐Kuang; Ho, Hao‐Chung; Cheng, Chen‐Li; Yang, Chi‐Rei; Chen, Cheng‐Che; Wang, Shu‐Chi; Lin, Chia‐Yen; Hung, Sheng‐Chun; Hsu, Chiann‐Yi; Chen, Chun‐Jung
• Is Part Of: BioFactors. Volume 45:Number 1(2019)
• Page Start: 62
• Page End: 68
• Publication Date: 2018-10-17
• Subjects: end‐stage renal disease -- fibroblast growth factor -- urothelial carcinoma; Vitamins -- Physiological effect -- Periodicals; Trace elements -- Physiological effect -- Periodicals; Growth factors -- Physiological effect -- Periodicals; Plant growth promoting substances -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Nutritional Physiological Phenomena -- Periodicals; Trace Elements -- metabolism -- Periodicals; Vitamins -- metabolism -- Periodicals; Molecular Biology -- Periodicals; 612.399
• DOI: 10.1002/biof.1460
• Languages: English
• ISSNs: 0951-6433

Abstract

ABSTRACT: Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls ( P = 0.015, <0.001 and < 0.001, respectively). In the subgroup analysis, the FGF19 and FGF21 levels were significantly higher in end‐stage renal disease UC patients, while FGF21 was also higher in the UC patients with cardiovascular diseases and history of recurrent UC. In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively). In UC patients, serum FGF19 level was significantly lower, while FGF21 and 23 were significantly higher, than respective levels in healthy controls. All three markers may serve as good predictors of UC occurrence, and FGF21 level was associated with disease recurrence. © 2018 BioFactors, 45(1):62–68, 2019